Summary

Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics (IVD). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease IVD market from 2025 to 2032.

Key Insights:

•Infectious Disease IVD Market Size (2025E): USD 46.6 Billion
•Projected Market Value (2032F): USD 64.1 Billion
•Global Market Growth Rate (CAGR 2025 to 2032): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

Infectious disease in-vitro diagnostics play a crucial role in the rapid and accurate detection of pathogens responsible for infections such as HIV, hepatitis, influenza, tuberculosis, and emerging viral threats like SARS-CoV-2. These diagnostics encompass molecular assays, immunoassays, and point-of-care testing technologies, enabling early diagnosis, guiding treatment decisions, and facilitating infection control efforts. The infectious disease IVD market caters to hospitals, clinical laboratories, diagnostic centers, and point-of-care settings, offering a diverse array of test kits, reagents, instruments, and software solutions. Market growth is driven by the rising prevalence of infectious diseases, increased demand for rapid and accurate testing, and technological advancements in diagnostic platforms, improving sensitivity, specificity, and turnaround times.

Market Growth Drivers:

The global infectious disease IVD market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and heightened awareness of early detection and disease management. The increasing burden of antibiotic-resistant infections, the need for precise diagnostics in outbreak scenarios, and robust government initiatives supporting infectious disease surveillance and screening further accelerate market growth. Technological progress in molecular diagnostics, such as next-generation sequencing and multiplex PCR, enables simultaneous detection of multiple pathogens, enhancing clinical decision-making and patient outcomes. Moreover, the expanding use of point-of-care tests for infectious disease screening in decentralized healthcare settings contributes significantly to market expansion, offering convenience and faster diagnosis, especially in resource-limited regions.

Market Restraints:

Despite promising growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory frameworks, complex approval processes, and reimbursement limitations in certain regions. Variations in regulatory requirements across countries create barriers for global market penetration and increase development timelines and costs for manufacturers. Additionally, the high cost of advanced molecular diagnostic systems and tests can restrict adoption, particularly in low- and middle-income countries where budget constraints affect healthcare spending. Moreover, concerns around test accuracy, false-positive or false-negative results, and quality control in decentralized settings pose ongoing challenges for market players striving to maintain diagnostic reliability and clinical trust.

Market Opportunities:

The infectious disease IVD market presents significant growth opportunities driven by technological innovations, global health priorities, and evolving diagnostic needs. The integration of digital health tools, such as cloud-based data management and artificial intelligence-driven diagnostic algorithms, improves diagnostic accuracy, enables remote analysis, and supports disease surveillance and outbreak tracking. Furthermore, rising investment in research and development for novel biomarkers, rapid diagnostic tests, and syndromic testing panels expands the market scope and addresses unmet clinical needs. The shift toward personalized medicine, increased public-private collaborations, and growing emphasis on preparedness for emerging infectious diseases create avenues for market players to develop innovative solutions and strengthen market presence in the dynamic infectious disease diagnostics landscape.

Key Questions Answered in the Report:

•What are the primary factors driving the growth of the infectious disease IVD market globally?
•Which test types and applications are driving the adoption of infectious disease diagnostics across various healthcare settings?
•How are technological advancements reshaping the competitive landscape of the infectious disease IVD market?
•Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
•What are the emerging trends and future prospects in the global infectious disease IVD market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.

Key Companies Profiled:

•QIAGEN
•Becton, Dickinson and Company
•bioMérieux SA
•F. Hoffmann-La Roche, Ltd.
•Hologic, Inc. (Gen Probe)
•Abbott
•Quidel Corporation
•Siemens Healthineers AG
•Bio-Rad Laboratories, Inc.
•Danaher
•OraSure Technologies, Inc.

Infectious Disease IVD Market Research Segmentation:

The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.

By Product Type

•Instruments
•Reagents
•Software and Services

By Technology

•Immunoassay
•Molecular Diagnostics
•Microbiology
•Others

By Application

•MRSA
•Clostridium Difficile
•Respiratory Virus
•TB and Drug-resistant TB
•Gonorrhea
•HPV
•HIV
•Hepatitis C
•Hepatitis B
•COVID-19
•Others

By End User

•Point-of-care
•Central Laboratories
•Others

By Region

•North America
•Europe
•East Asia
•South Asia and Oceania
•Latin America
•Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Infectious Disease In-vitro Diagnostics Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025–2032
4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
4.3.3.1. Instruments
4.3.3.2. Reagents
4.3.3.3. Software and Services
4.3.4. Market Attractiveness Analysis: Product Type
4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
4.4.3.1. Immunoassay
4.4.3.2. Molecular Diagnostics
4.4.3.3. Microbiology
4.4.3.4. Others
4.4.4. Market Attractiveness Analysis: Technology
4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
4.5.3.1. MRSA
4.5.3.2. Clostridium Difficile
4.5.3.3. Respiratory Virus
4.5.3.4. TB and Drug-resistant TB
4.5.3.5. Gonorrhea
4.5.3.6. HPV
4.5.3.7. HIV
4.5.3.8. Hepatitis C
4.5.3.9. Hepatitis B
4.5.3.10. COVID-19
4.5.3.11. Others
4.5.4. Market Attractiveness Analysis: Application
4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
4.6.3.1. Point-of-care
4.6.3.2. Central Laboratories
4.6.3.3. Others
4.6.4. Market Attractiveness Analysis: End User
5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Infectious Disease In-vitro Diagnostics Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Product Type
6.2.3. By Technology
6.2.4. By Application
6.2.5. By End User
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
6.4.1. Instruments
6.4.2. Reagents
6.4.3. Software and Services
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
6.5.1. Immunoassay
6.5.2. Molecular Diagnostics
6.5.3. Microbiology
6.5.4. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
6.6.1. MRSA
6.6.2. Clostridium Difficile
6.6.3. Respiratory Virus
6.6.4. TB and Drug-resistant TB
6.6.5. Gonorrhea
6.6.6. HPV
6.6.7. HIV
6.6.8. Hepatitis C
6.6.9. Hepatitis B
6.6.10. COVID-19
6.6.11. Others
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
6.7.1. Point-of-care
6.7.2. Central Laboratories
6.7.3. Others
6.8. Market Attractiveness Analysis
7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Product Type
7.2.3. By Technology
7.2.4. By Application
7.2.5. By End User
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
7.4.1. Instruments
7.4.2. Reagents
7.4.3. Software and Services
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
7.5.1. Immunoassay
7.5.2. Molecular Diagnostics
7.5.3. Microbiology
7.5.4. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
7.6.1. MRSA
7.6.2. Clostridium Difficile
7.6.3. Respiratory Virus
7.6.4. TB and Drug-resistant TB
7.6.5. Gonorrhea
7.6.6. HPV
7.6.7. HIV
7.6.8. Hepatitis C
7.6.9. Hepatitis B
7.6.10. COVID-19
7.6.11. Others
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
7.7.1. Point-of-care
7.7.2. Central Laboratories
7.7.3. Others
7.8. Market Attractiveness Analysis
8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Product Type
8.2.3. By Technology
8.2.4. By Application
8.2.5. By End User
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
8.4.1. Instruments
8.4.2. Reagents
8.4.3. Software and Services
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
8.5.1. Immunoassay
8.5.2. Molecular Diagnostics
8.5.3. Microbiology
8.5.4. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
8.6.1. MRSA
8.6.2. Clostridium Difficile
8.6.3. Respiratory Virus
8.6.4. TB and Drug-resistant TB
8.6.5. Gonorrhea
8.6.6. HPV
8.6.7. HIV
8.6.8. Hepatitis C
8.6.9. Hepatitis B
8.6.10. COVID-19
8.6.11. Others
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
8.7.1. Point-of-care
8.7.2. Central Laboratories
8.7.3. Others
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Product Type
9.2.3. By Technology
9.2.4. By Application
9.2.5. By End User
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
9.4.1. Instruments
9.4.2. Reagents
9.4.3. Software and Services
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
9.5.1. Immunoassay
9.5.2. Molecular Diagnostics
9.5.3. Microbiology
9.5.4. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
9.6.1. MRSA
9.6.2. Clostridium Difficile
9.6.3. Respiratory Virus
9.6.4. TB and Drug-resistant TB
9.6.5. Gonorrhea
9.6.6. HPV
9.6.7. HIV
9.6.8. Hepatitis C
9.6.9. Hepatitis B
9.6.10. COVID-19
9.6.11. Others
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
9.7.1. Point-of-care
9.7.2. Central Laboratories
9.7.3. Others
9.8. Market Attractiveness Analysis
10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Product Type
10.2.3. By Technology
10.2.4. By Application
10.2.5. By End User
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
10.4.1. Instruments
10.4.2. Reagents
10.4.3. Software and Services
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
10.5.1. Immunoassay
10.5.2. Molecular Diagnostics
10.5.3. Microbiology
10.5.4. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
10.6.1. MRSA
10.6.2. Clostridium Difficile
10.6.3. Respiratory Virus
10.6.4. TB and Drug-resistant TB
10.6.5. Gonorrhea
10.6.6. HPV
10.6.7. HIV
10.6.8. Hepatitis C
10.6.9. Hepatitis B
10.6.10. COVID-19
10.6.11. Others
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
10.7.1. Point-of-care
10.7.2. Central Laboratories
10.7.3. Others
10.8. Market Attractiveness Analysis
11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Product Type
11.2.3. By Technology
11.2.4. By Application
11.2.5. By End User
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
11.4.1. Instruments
11.4.2. Reagents
11.4.3. Software and Services
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
11.5.1. Immunoassay
11.5.2. Molecular Diagnostics
11.5.3. Microbiology
11.5.4. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
11.6.1. MRSA
11.6.2. Clostridium Difficile
11.6.3. Respiratory Virus
11.6.4. TB and Drug-resistant TB
11.6.5. Gonorrhea
11.6.6. HPV
11.6.7. HIV
11.6.8. Hepatitis C
11.6.9. Hepatitis B
11.6.10. COVID-19
11.6.11. Others
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
11.7.1. Point-of-care
11.7.2. Central Laboratories
11.7.3. Others
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
12.3.1. QIAGEN
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Becton, Dickinson and Company
12.3.3. bioMérieux SA
12.3.4. F. Hoffmann-La Roche, Ltd.
12.3.5. Hologic, Inc. (Gen Probe)
12.3.6. Abbott
12.3.7. Quidel Corporation
12.3.8. Siemens Healthineers AG
12.3.9. Bio-Rad Laboratories, Inc.
12.3.10. Danaher
12.3.11. OraSure Technologies, Inc.
12.3.12. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations